bioAffinity signs distribution agreement with AvMEDICAL for CyPath Lung in federal healthcare

bioAffinity Technologies, Inc.

Distribution agreement with AvMEDICAL (SDVOSB) to market CyPath Lung to federal agencies, including VA medical centers.
AvMEDICAL's sales force and IDIQ contract access expected to expand government procurement of CyPath Lung.
CyPath Lung clinical data: 92% sensitivity, 87% specificity, 88% accuracy, 99% NPV in high-risk patients with nodules <20mm.
VA context: ~8,000 veterans diagnosed with lung cancer annually; ~5,000 die; early detection goal.
Co-branded marketing and AvMEDICAL promotion to federal customers; no financial terms disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.